

What is claimed is:

1. A liposome wherein a compound containing a polyalkylene glycol moiety is bonded through a thioether group to a liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded compound is 15 to 50 mole% based on one mole of the maleimidated lipid contained in the liposome.

2. The liposome according to claim 1, wherein the amount of the bonded compound is 15 to 30 mole% based on one mole of the maleimidated lipids.

3. The liposome according to claim 1 or claim 2, which is obtained by reacting a maleimide group of the maleimidated lipid with the compound containing a polyalkylene glycol moiety introduced with a thiol group.

4. The liposome according to any one of claims 1 to 3, wherein the compound is bonded to a surface of the liposome.

5. The liposome according to any one of claims 1 to 4, wherein the polyalkylene glycol is polyethylene glycol.

6. The liposome according to claim 5, wherein the compound has two polyethylene glycol groups.

7. The liposome according to claim 6, wherein the polyethylene glycol has a molecular weight of 2,000 to 7,000 daltons.

8. The liposome according to claim 6, wherein the polyethylene glycol has a molecular weight of about 5,000 daltons.

9. The liposome according to any one of claims 1 to 8, wherein an antibody is further bonded on a surface of the liposome.

10. A liposome wherein an antibody is bonded through a thioether group to a liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded antibody is 0.1 to 2 mole% based on one mole of the maleimidated lipids contained in the liposome.

11. The liposome according to claim 10, wherein an amount of the bonded antibody is 0.4 to 0.7 mole% based on one mole of the maleimidated lipids.

12. The liposome according to claim 10 or claim 11, which is obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving

from the antibody to form a thioether bond.

13. The liposome according to any one of claims 10 to 12, wherein the antibody is a GAH antibody,

14. The liposome according to any one of claims 10 to 13, wherein the antibody is a F(ab')₂ antibody fragment.

15. The liposome according to any one of claims 10 to 14, wherein a compound containing a polyalkylene glycol moiety is further bonded to a surface of the liposome.

16. A liposome wherein a compound containing a polyalkylene glycol moiety and an antibody are bonded through thioether groups to a liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded compound is 15 to 30 mole% and an amount of the bonded antibody is 0.4 to 0.7 mole% based on one mole of the maleimidated lipids contained in the liposome.

17. The liposome according to claim 16, which is obtained by reacting a maleimide group of the maleimidated lipid with the compound containing a polyalkylene glycol moiety introduced with a thiol group.

18. The liposome according to claim 16 or claim 17, wherein the compound is bonded to a surface of the liposome.

19. The liposome according to any one of claims 16 to 18, wherein the polyalkylene glycol is polyethylene glycol.

20. The liposome according to claim 19, wherein the compound has two polyethylene glycol groups.

21. The liposome according to claim 20, wherein the polyethylene glycol has a molecular weight of 2,000 to 7,000 daltons.

22. The liposome according to claim 20, wherein the polyethylene glycol has a molecular weight of about 5,000 daltons.

23. The liposome according to any one of claims 16 to 22, which is a liposome obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond.

24. The liposome according to any one of claims 16 to 23, wherein the antibody is a GAH antibody.

25. The liposome according to any one of claims 16 to 24, wherein the

antibody is a $F(ab')_2$ antibody fragment.

25. 26. A medicament for treatment of cancer according to any one of claims 1 to

27. The medicament according to claim 26, wherein the cancer is stomach cancer or colon cancer.

28. A method for treatment of cancer which comprises the use of the liposome according to any one of claims 1 to 27.